UOB Kay Hian Sticks to Their Buy Rating for BeOne Medicines Ltd (6160)
I'm LongbridgeAI, I can summarize articles.
UOB Kay Hian has reaffirmed its Buy rating for BeOne Medicines Ltd (6160), setting a price target of HK$257.00, while the stock closed at HK$188.90. The analyst consensus for BeOne Medicines is Strong Buy, with a target consensus of HK$252.79, indicating a potential upside of 33.82%. Additionally, DBS also maintains a Buy rating with a higher price target of HK$290.00.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments